Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Are mitochondrial therapeutics about to go mainstream?

37:47
 
Share
 

Manage episode 472586786 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough?

Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. He joins 'Beyond Biotech' to talk cell mitophagy, biotech agility, and innovation in tackling neurodegenerative disease.

00:42 Introducing Klaus Dugi

02:51 Lessons learned in top pharma

05:10 The gap that Vandria seeks to fill

06:21 Mitochondrial therapeutics

07:45 Mitophagy inducers and how they work

14:53 Comparing approaches to treating neurodegenerative diseases

17:20 Aging, longevity, and healthy life years

25:26 Challenges ahead

27:31 Performance enhancement and resilience

31:15 Towards the mainstream?

34:35 Looking forward for Vandria

36:02 Developments to watch out for in mitochondrial therapeutics

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Chapters

1. Are mitochondrial therapeutics about to go mainstream? (00:00:00)

2. Introducing Klaus Dugi (00:00:42)

3. Lessons learned in top pharma (00:02:51)

4. The gap that Vandria seeks to fill (00:05:10)

5. Mitochondrial therapeutics (00:06:21)

6. Mitophagy inducers and how they work (00:07:45)

7. Comparing approaches to treating neurodegenerative diseases (00:14:53)

8. Aging, longevity, and healthy life years (00:17:20)

9. Challenges ahead (00:25:26)

10. Performance enhancement and resilience (00:27:31)

11. Towards the mainstream? (00:31:15)

12. Looking forward for Vandria (00:34:35)

13. Developments to watch out for in mitochondrial therapeutics (00:36:02)

146 episodes

Artwork
iconShare
 
Manage episode 472586786 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough?

Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. He joins 'Beyond Biotech' to talk cell mitophagy, biotech agility, and innovation in tackling neurodegenerative disease.

00:42 Introducing Klaus Dugi

02:51 Lessons learned in top pharma

05:10 The gap that Vandria seeks to fill

06:21 Mitochondrial therapeutics

07:45 Mitophagy inducers and how they work

14:53 Comparing approaches to treating neurodegenerative diseases

17:20 Aging, longevity, and healthy life years

25:26 Challenges ahead

27:31 Performance enhancement and resilience

31:15 Towards the mainstream?

34:35 Looking forward for Vandria

36:02 Developments to watch out for in mitochondrial therapeutics

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Chapters

1. Are mitochondrial therapeutics about to go mainstream? (00:00:00)

2. Introducing Klaus Dugi (00:00:42)

3. Lessons learned in top pharma (00:02:51)

4. The gap that Vandria seeks to fill (00:05:10)

5. Mitochondrial therapeutics (00:06:21)

6. Mitophagy inducers and how they work (00:07:45)

7. Comparing approaches to treating neurodegenerative diseases (00:14:53)

8. Aging, longevity, and healthy life years (00:17:20)

9. Challenges ahead (00:25:26)

10. Performance enhancement and resilience (00:27:31)

11. Towards the mainstream? (00:31:15)

12. Looking forward for Vandria (00:34:35)

13. Developments to watch out for in mitochondrial therapeutics (00:36:02)

146 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play